Sage Journals: Discover world-class research

Retricted access

Research article

First published 2021-8

US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments,2009–2018

Joshua J Skydel, Audrey D Zhang, Sanket S Dhruva [...]

Clinical Trials

Retricted access

Research article

First published 2018-6

The US Food and Drug Administration’s expedited approval programs: Evidentiary standards,regulatory trade-offs,and potential improvements

Joshua D Wallach, Joseph S Ross, Huseyin Naci

Clinical Trials

Retricted access

Research article

First published 2014-10

Ethical considerations in design of a study to evaluate a US Food and Drug Administration–approved indication: Antivenom versus placebo for copperhead envenomation

Charles J Gerardo, Eric J Lavonas, Ross E McKinney

Clinical Trials

Retricted access

Research article

First published 2009-11

Computational Toxicology Approaches at the US Food and Drug Administration a

Chihae Yang, Luis G. Valerio, Kirk B. Arvidson

Alternatives to Laboratory Animals

Retricted access

Editorial

First published 2015-12

US Food and Drug Administration Web Site: A Primer for Pharmacists

James Leonard, Danial E. Baker

Hospital Pharmacy

Free access

Review article

First published 2015-8

Carcinogenicity of psychotropic drugs: A systematic review of US Food and Drug Administration–required preclinical in vivo studies

Andrea Amerio, Juan Francisco Gálvez, Anna Odone [...]

Australian & New Zealand Journal of Psychiatry

Retricted access

Research article

First published 2018-6

The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation

Joshua D Wallach, Joseph S Ross, Huseyin Naci

Clinical Trials

Free access

Research article

First published 2018-7

Anticipating Industry Arguments: The US Food and Drug Administration’s Authority to Reduce Nicotine Levels in Cigarettes

Micah L. Berman, Patricia J. Zettler, David L. Ashley

Public Health Reports®

Open access

Research article

First published 2016

When are medical apps medical? Off-label use and the Food and Drug Administration

William H Krieger

DIGITAL HEALTH

Retricted access

Research article

First published 2017-04

Using Chemoinformatics,Bioinformatics,and Bioassay to Predict and Explain the Antibacterial Activity of Nonantibiotic Food and Drug Administration Drugs

Nour Aldin Kahlous, Muhammad Al Mohdi Bawarish, Muhammad Arabi Sarhan [...]

ASSAY and Drug Development Technologies

Search results